Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants by Li, Wei et al.
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 94-98Cerebrospinal Fluid Biomarkers
Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer’s disease
biomarker amyloid b1-42 in Alzheimer’s Disease Neuroimaging
Initiative participantsWei Lia,*, Shannon L. Risacherb, Sujuan Gaoc, Stephen L. Boehm IId, Jeffrey S. Elmendorfe,f,
Andrew J. Saykinb, for the Alzheimer’s Disease Neuroimaging Initiative1
aDepartment of Clinical and Diagnostic Sciences, Physician Assistant Studies, School of Health Professions, University of Alabama at Birmingham,
Birmingham, AL, USA
bDepartment of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana Alzheimer Disease Center, Indiana University School of Medicine,
Indianapolis, IN, USA
cDepartment of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA
dDepartment of Psychology, School of Science, Indiana University-Purdue University Indianapolis, Indianapolis, IN, USA
eDepartment of Cellular and Integrative Physiology, Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine,
Indianapolis, IN, USA
fDepartment of Biochemistry and Molecular Biology, Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine,
Indianapolis, IN, USAAbstract Introduction: Type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer’s disease. Cerebro-On behalf of all au
conflict of interest.
1Data used in pre
heimer’s Disease Neu
c.edu). As such, the in
and implementation of
analysis or writing of
can be found at: htt
ply/ADNI_Acknowled
*Corresponding au
E-mail address: w
https://doi.org/10.1016
2352-8729/ 2017 T
license (http://creativespinal fluid (CSF) amyloid b (Ab) 1-42 is an important Alzheimer’s disease biomarker. However,
it is inconclusive on how T2DM is related to CSF Ab1-42.
Methods: Participants with T2DM were selected from the Alzheimer’s Disease Neuroimaging
Initiative by searching keywords from the medical history database. A two-way analysis of covari-
ance model was used to analyze how T2DM associates with CSF Ab1-42 or cerebral cortical Ab.
Results: CSFAb1-42 was higher in the T2DM group than the nondiabetic group. The inverse relation
between CSF Ab1-42 and cerebral cortical Ab was independent of T2DM status. Participants with
T2DMhad a lower cerebral cortical Ab in anterior cingulate, precuneus, and temporal lobe than controls.
Discussion: T2DM is positively associated with CSF Ab1-42 but negatively with cerebral cortical
Ab. The decreased cerebral cortical Ab associated with T2DM is preferentially located in certain
brain regions.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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In 1999, the Rotterdam Study found that type 2 diabetes
mellitus (T2DM) could double the risk of Alzheimer’s dis-
ease (AD) [1]. In 2011, another study reported that AD
risk increased 60% in patients with T2DM over the nondia-
betics [2]. Further, a high prevalence of T2DM in patients
with AD is congruent with T2DM as an AD risk factor [3].
Cerebrospinal fluid (CSF) amyloid b (Ab) 1-42 has been
shown as a sensitive biomarker for diagnosing AD [4] andimer’s Association. This is an open access article under the CC BY-NC-ND
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plaints to progress to AD [5]. However, a recent study did not
find the association between T2DM and CSF Ab1-42 [6].
Using data from participants enrolled in Alzheimer’s Dis-
ease Neuroimaging Initiative (ADNI), we investigated the
relationship between CSF Ab1-42 with T2DM and baseline
cognition diagnosis. Ab load in cerebral cortex as well as its
subregions was also compared between participants with
and without T2DM. Our findings provide important insight
into CSF Ab1-42 as an AD biomarker and its relation to
the cerebral cortical Ab, especially for patients with T2DM.2. Methods
2.1. ADNI
Demographic and imaging data were downloaded from the
ADNI database (adni.loni.usc.edu). As an ongoing project,
ADNI was launched in 2003 and has been sponsored by the
following agencies: National Institute onAging, National Insti-
tute of Biomedical Imaging and Bioengineering, Food and
Drug Administration, private pharmaceutical companies, and
nonprofit organizations. The primary goal of the ADNI has
been to test whether serial magnetic resonance imaging, posi-
tron emission tomography (PET), biological markers, and clin-
ical and neuropsychological assessment can be combined to
measure the progression of mild cognitive impairment (MCI)
and early AD. In three phases (1, GO, and 2) and from over
50 sites across the United States and Canada, the ADNI has re-
cruited more than 1800 adult participants. The participants are
older adults (aged 55–90 years) with normal cognition,MCI, or
mild AD. Further information can be found at http://www.
adni-info.org/ and in previous reports [7–12].
2.2. Selection of T2DM participants
The following search terms were used in the medical his-
tory database to screen the ADNI participants: diabetes, dia-
betic, and insulin. Based on the medical history information
(age at onset of diabetes, clinical diagnosis, and/or use of
diabetic medications), 159 participants from the ADNI
were found to have T2DM at the screening visit (Table 1).
In these diabetic participants, 76.73% (122/159) were beingTable 1
Participant demographics and clinical information
Participant features T2DM
N 77
Age (,75:75–80:.80)
(Mean 6 SD)
53 (68.83%):18 (23.38%):6 (7.8
(70.48 6 6.71)
Gender (M: F) 46:31
APOE 34 carrier status (1/2) 39:37
APOE genotype (32/32: 32/33: 33/33: 32/34:
33/34: 34/34)
0 (0%):4 (5.19%):33 (42.86%):
32 (41.56%):6 (7.80%)
Education 15.74 6 2.44
HC: MCI: AD 10:54:2
Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein epsilon; HC, he
litus; SD, standard deviation.treated with antidiabetic medications. These diabetic partic-
ipants had an average fasting glucose level between 110 and
120 mg/dL at the baseline and at 12-, 24-, and 36-month
follow-up visits.
2.3. CSFAb1-42 measures
CSF samples were collected by following standard pro-
cedures stated in the ADNI protocols. AD biomarkers
including Ab1-42 were measured at the ADNI Biomarkers
Core located at the University of Pennsylvania. In brief, all
CSF samples were collected from the participants after at
least a 6-hour fasting period. The CSF samples were
analyzed by following storing, shipping, and testing pro-
cedures and with parallel strict quality control steps. To
date, eight batches of data on CSF biomarkers have been
released from the Biomarkers Core. Only baseline CSF
Ab1-42 and corresponding cerebral cortical Ab PET mea-
sures were being analyzed in the present study.2.4. 18F florbetapir AV45 PET imaging and analysis
Preprocessed florbetapir imaging data were downloaded
from the LONI ADNI site (http://adni.loni.usc.edu). Data
preprocessing information is available online (adni.loni.
ucla.edu/about-data-samples/image-data/). Briefly, image
data were acquired in four 5-min frames 50–70 minutes af-
ter injection of approximately 10 mCi of 18F florbetapir, the
four frames were co-registered to one another, averaged,
interpolated to a uniform image and voxel size
(160 ! 106 ! 96, 1.5 mm3), and smoothed to a uniform
resolution (8 mm FWHM) to account for differences be-
tween scanners [13].
For quantifying cerebral cortical Ab, preprocessed florbe-
tapir image data and co-registered structural magnetic reso-
nance images were analyzed using Freesurfer software,
version 4.5.0 (surfer.nmr.mgh.harvard.edu/) as described
before [14] and online (adni.loni.ucla.edu/research/
pet-post-processing/). The mean Ab retention, measured
by the florbetapir AV45 standardized uptake value ratio,
was normalized to the whole cerebellum as a summary mea-
sure of florbetapir retention for each participant.Nondiabetics
735
0%) 454 (61.77%):179 (24.35%):102 (13.88%) (72.17 6 7.37)
384:351
327:404
1 (1.30%): 1 (0.14%):59(8.03%):344 (46.80%):9 (1.22%):
245 (33.33%):73 (9.93%)
16.31 6 2.62
151:493:7
althy control; MCI, mild cognitive impairment; T2DM, type 2 diabetes mel-
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SPSS software (version 24.0) was used for all statistical
analyses. First, a two-way analysis of covariance model
was utilized to evaluate effects of T2DM and baseline diag-
nostic group (healthy control [HC], MCI, and AD) on CSF
Ab1-42. Age, gender, and apolipoprotein epsilon (APOE)
ε4 carrier status (1/2) were controlled as possible con-
founding factors (Table 1). Data were shown in the form
of mean 6 standard deviation, and P , .05 was considered
as significant in all statistical analyses. Figures were created
using Microsoft Excel or SigmaPlot (version 10.0).2.6. Standard protocol approvals, registrations, and
patient consents
Written informed consent was obtained from all partici-
pants (or guardians of participants) participating in the study
according to the Declaration of Helsinki (consent for research).3. Results
CSF Ab1-42 was affected by both T2DM (P 5 .001) and
baseline diagnosis (P5 .001). CSFAb1-42 in the T2DMgroup
was 204.35 6 9.40 pg/mL (95% CI: 185.89–222.80 pg/mL,
n5 76), which is higher than its level in the nondiabetic group
of 168.59 6 4.49 pg/mL (95% CI: 159.76–177.40 pg/mL,
n 5 731, P 5 .001) (Fig. 1). It is worthy to note that T2DM
did not interact with baseline diagnosis significantly for its ef-
fects on CSFAb1-42 (P 5 .053).
Then cerebral corticalAbwasanalyzed to examine its corre-
lation to the CSF Ab1-42 for participants with and without
T2DM, respectively. For participants with T2DM, the correla-
tion coefficient was 20.669 (n 5 77, P , .005). By contrast,
the correlation coefficient was20.705 (n5 735, P, .005) for
participants without T2DM. For participants with T2DM, cere-
bral corticalAb (indicatedby theflorbetapirAV45 standardized
uptakevalueratio)was1.4560.04(95%CI:1.38–1.52,n574),
which is significantly lower than the counterpart measure inC
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Fig. 1. Participants with T2DM have a higher CSF Ab1-42 than those
without T2DM. Abbreviations: Ab42, Ab 1-42; CSF, cerebrospinal fluid;
T2DM, type 2 diabetes mellitus.participants without T2DM of 1.53 6 0.02 (95% CI: 1.50–
1.57, n5 724,P5 .045) (Fig. 2).
Subsequently, cerebral cortical Ab load was compared in
different brain regions (anterior cingulate, frontal lobe, limbic
lobe, occipital lobe, parietal lobe, posterior cingulate, precu-
neus, and temporal lobe) to examine if the differences be-
tween participants with and without T2DM were
preferentially distributed in some regions than others
(Table 2). A lower load of Ab was seen in participants with
T2DM than in those without T2DM from all examined brain
regions (Table 2). However, significant differences were only
observed in brain regions of anterior cingulate, precuneus, and
temporal lobe between participants with and without T2DM.4. Discussion
Amyloid plaque is one of the classical pathological bio-
markers for AD. Ab, the major protein component of amy-
loid plaque, is generated from a sequential cleavage of
amyloid precursor protein by b- and g-secretase [15]. The
amyloid deposited in neuritic plaques exists predominantly
as the Ab1-42 form, which is less soluble and more likely
to aggregate than the Ab1-40 form. More importantly,
CSF Ab1-42 has been shown as a useful pathological
biomarker for AD [16,17].
CSF Ab1-42 is higher in participants with T2DM than
those without T2DM. However, the increased concentration
of CSF Ab1-42 is not due to CSF volume changes, as the
CSF volume is comparable between participants with
T2DM and nondiabetic controls (Supplementary Fig. 1). It
is noteworthy that CSF Ab1-42 has also been reported to
be higher in type 1 diabetes mellitus [18]. Therefore,
increased CSF Ab1-42 level is more likely associated with
diabetes-related pathological changes (e.g. hyperglycemia)
common in both types of diabetes.
It is known that microvascular lesions associated with
T2DM can contribute to an increased blood–brain barrier
permeability [19,20], which can change the distribution of
biomarkers including Ab1-42 as well as the cognitiveRV
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Fig. 2. Cortical Ab, measured by the florbetapir AV45 SUVR, was
compared between participants with and without T2DM. Abbreviations:
SUVR, standardized uptake value ratio; T2DM, type 2 diabetes mellitus.
Table 2
The mean Ab, measured by the florbetapir AV45 standardized uptake value ratio, was compared between participants with and without T2DM in different brain
regions
Brain region T2DM (n 5 74) Nondiabetics (n 5 724) P value
Anterior cingulate 1.64 6 0.05 (95% CI: 1.54–1.74) 1.75 6 0.02 (95% CI: 1.70–1.80) .043
Frontal lobe 1.47 6 0.04 (95% CI: 1.39–1.54) 1.55 6 0.02 (95% CI: 1.51–1.59) .054
Limbic lobe 1.57 6 0.04 (95% CI: 1.50–1.65) 1.64 6 0.02 (95%CI: 1.61–1.68) .104
Occipital lobe 1.35 6 0.03 (95% CI: 1.28–1.41) 1.42 6 0.02 (95% CI: 1.39–1.45) .057
Parietal lobe 1.43 6 0.04 (95% CI: 1.34–1.51) 1.52 6 0.02 (95% CI: 1.48–1.56) .062
Posterior cingulate 1.50 6 0.05 (95% CI: 1.41–1.59) 1.59 6 0.02 (95% CI: 1.55–1.63) .085
Precuneus 1.42 6 0.05 (95% CI: 1.33–1.52) 1.54 6 0.02 (95% CI: 1.50–1.59) .021
Temporal lobe 1.43 6 0.04 (95% CI: 1.35–1.51) 1.52 6 0.02 (95% CI: 1.48–1.56) .04
Abbreviations: Ab, amyloid b; T2DM, type 2 diabetes mellitus.
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impairments caused by the vascular defects might be
misdiagnosed as early stage AD [19]. For the ADNI partic-
ipants with T2DM, the prevalence of AD is low, but they still
have a higher AD risk than the same measure from the
nondiabetic participants.
Mean CSFAb1-42 level was previously shown to be signif-
icantly lower in the mild AD group or amnestic MCI group
than the control group [21]. Not surprisingly, a higher CSF
Ab1-42 was observed in the HC group than the MCI group
and the AD group in the present study (Supplementary
Fig. 2). However, CSF Ab1-42 was comparable between the
MCI and AD groups, and the data suggest that measuring
CSFAb1-42 is more useful for detecting a cognitive deteriora-
tion from HC to MCI than differentiating MCI from AD.
Although a lower CSF Ab1-42 was seen in participants
with either MCI or AD than in the HC group, comorbid
T2DM is related to a reversion of CSF Ab1-42 in those
with cognitive impairments (MCI or AD). However, a
similar relation between T2DM and cerebral cortical Ab
was not observed. More interestingly, CSF Ab1-42 is
inversely correlated with cerebral cortical Ab, and the rela-
tionship is independent of T2DM status.
Our results showed that T2DM is associated with a unique
pattern of changes in CSF Ab1-42 as well as a preferential
distribution of decreased cerebral cortical Ab in certain brain
regions. Although the exact mechanism is not clear, immune
function might play an important role in leading to these
changes as the Ab autoantibody increases for more than
45% in patients with T2DM in comparison with controls [22].
The present study is limited by its cross-sectional design.
A longitudinal study design may be more powerful for
evaluating CSF Ab1-42 as a biomarker of early cognitive
impairment in people with or without T2DM. In addition,
data on CSF Ab1-42 and type 1 diabetes mellitus will also
be useful for defining CSF Ab1-42 as an AD biomarker.
In conclusion, CSF Ab1-42 is positively associated with a
T2DM status. The pattern of CSFAb1-42 and cerebral cortical
Ab changes in peoplewith T2DMsuggests that T2DMmay in-
crease AD risk through a disease-associated pathological
mechanism. However, the underlying pathological mechanism
for CSF Ab1-42 and cerebral cortical Ab warrants investiga-
tion in subjects with and without T2DM in the future.Acknowledgments
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1. Systematic review: Although type 2 diabetes mellitus
(T2DM) is a risk factor for Alzheimer’s disease, it is
controversial on how T2DM relates to Alzheimer’s
disease biomarker cerebrospinal fluid (CSF) amyloid
b (Ab) 1-42. The authors reviewed available scarce
evidence on how T2DM is associated with CSF
Ab1-42 using PubMed as the main literature source.
The relevant citations are appropriately cited.
2. Interpretation: T2DM is positively associated with
the CSF Ab1-42 but negatively associated with the
cortical Ab. The decreased cortical Ab associated
with T2DM is preferentially located in anterior
cingulate, precuneus, and temporal lobe.
3. Future directions: The underlying pathological
mechanism for CSFAb1-42 and cortical Ab changes
is to be investigated in patients with and without
T2DM in the future.
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